PURPOSE

This preliminary study evaluated effect sizes of differences in circulating cell-free DNA (cfDNA) levels in blood and urine between older adults with and without sarcopenia.

METHODS

This was a subanalysis of the 2021 Itabashi Longitudinal Study on Aging. Twenty-four participants were selected conveniently and classified using the Asian Working Group for Sarcopenia (AWGS) 2019 criteria (sarcopenia, N = 12; non-sarcopenia, N = 10).

Plasma and urinary cfDNA were quantified by real-time quantitative polymerase chain reaction (qPCR).

RESULTS

cfDNA measures showed substantial inter-individual variability, and no clear between-group differences were observed. Plasma cfDNA demonstrated a moderate positive correlation with skeletal muscle mass index (r = 0.43, p = 0.03), but the clinical relevance remains uncertain given the small sample size.

CONCLUSIONS

Larger, well-powered longitudinal studies are needed to clarify whether cfDNA, including mitochondrial and nuclear components, can serve as a biomarker of muscle health and sarcopenia risk in older adults.